Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

   Trade now with Barclays Stockbrokers   Trade now with Barclays   Sponsored by Barclays Stockbrokers

2,608.00p
   
  • Change Today:
    -12.00p
  • 52 Week High: 2,992.00p
  • 52 Week Low: 2,098.00p
  • Currency: UK Pounds
  • Shares Issued: 65.05m
  • Volume: 492,097
  • Market Cap: £1,696.55m
  • RiskGrade: 174
  • Beta: 0.00

Genus Overview

Genus applies science to animal breeding. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors. It is a provider of bovine genetics and reproduction services, marketing in more than 70 countries.
Registrars: Equiniti

Key Personnel

CEO: Karim Bitar
Chairman: Robert (Bob) Lawson
General Counsel and Company Secretary: Dan Hartley
Group Finance Director: Stephen Wilson
Senior Non-Executive Director: Nigel Turner
Non-Executive Dir: Ian Charles, Lysanne Gray, Duncan Maskell, Lesley Knox, Lykele van der Broek

Contact Details

Address: Matrix House, Basing View, Basingstoke, Hampshire, United Kingdom, RG21 4DZ
Phone: +44 (0) 1256 347 100
Fax: +44 (0) 1256 477 385
Website: http://www.genusplc.com

Listings

Sector: Pharma and Biotech(LSE)
Index: techMARKFTSE 250FTSE 350FTSE All-ShareFTSE techMARK Focus
Overseas Listings: BATSLON:GNSL
ISIN: GB0002074580

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Genus Market Data

Currency UK Pounds
Share Price 2,608.00p
Change Today -12.00p
% Change -0.46 %
52 Week High 2,992.00p
52 Week Low 2,098.00p
Volume 492,097
Shares Issued 65.05m
Market Cap £1,696.55m
Beta 0.00
RiskGrade 174

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
95.62% below the market average95.62% below the market average95.62% below the market average95.62% below the market average95.62% below the market average
89.66% below the sector average89.66% below the sector average89.66% below the sector average89.66% below the sector average89.66% below the sector average
Price Trend
70.41% above the market average70.41% above the market average70.41% above the market average70.41% above the market average70.41% above the market average
57.38% above the sector average57.38% above the sector average57.38% above the sector average57.38% above the sector average57.38% above the sector average
Income
91.64% below the market average91.64% below the market average91.64% below the market average91.64% below the market average91.64% below the market average
69.23% below the sector average69.23% below the sector average69.23% below the sector average69.23% below the sector average69.23% below the sector average
Growth
71.18% below the market average71.18% below the market average71.18% below the market average71.18% below the market average71.18% below the market average
94.74% below the sector average94.74% below the sector average94.74% below the sector average94.74% below the sector average94.74% below the sector average

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 2
Sell 0
Strong Sell 0
Total 5
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Interim Final
Ex-Div 07-Mar-19 15-Nov-18
Paid 04-Apr-19 30-Nov-18
Amount 8.90p 17.90p

Trades for 14-Jun-2019

Time Volume / Share Price
16:35 9,672 @ 2,608.00p
16:29 16 @ 2,608.00p
16:26 92 @ 2,610.00p
16:26 40 @ 2,610.00p
16:26 47 @ 2,610.00p

Genus Key Personnel

Chair Robert (Bob) Lawson
CEO Karim Bitar

Top of Page